IO BIOTECH INC (IOBT) Stock Price & Overview

NASDAQ:IOBT • US4497781090

0.28 USD
-0.02 (-6.82%)
At close: Mar 9, 2026
0.288 USD
+0.01 (+2.86%)
After Hours: 3/9/2026, 8:13:10 PM

The current stock price of IOBT is 0.28 USD. Today IOBT is down by -6.82%. In the past month the price decreased by -20%. In the past year, price decreased by -68.14%.

IOBT Key Statistics

52-Week Range0.2053 - 2.79
Current IOBT stock price positioned within its 52-week range.
1-Month Range0.276 - 0.3977
Current IOBT stock price positioned within its 1-month range.
Market Cap
20.146M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
N/A
Dividend Yield
N/A

IOBT Stock Performance

Today
-6.82%
1 Week
-15.00%
1 Month
-20.00%
3 Months
-65.33%
Longer-term
6 Months -86.54%
1 Year -68.14%
2 Years -83.82%
3 Years -85.07%
5 Years N/A
10 Years N/A

IOBT Stock Chart

IO BIOTECH INC / IOBT Daily stock chart

IOBT Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to IOBT. When comparing the yearly performance of all stocks, IOBT is a bad performer in the overall market: 97.75% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating
IOBT Full Technical Analysis Report

IOBT Earnings

Next Earnings DateMar 16, 2026
Last Earnings DateNov 14, 2025
PeriodQ3 / 2025
EPS Reported-$0.13
Revenue Reported
EPS Surprise 60.66%
Revenue Surprise %
IOBT Earnings History

IOBT Forecast & Estimates

10 analysts have analysed IOBT and the average price target is 1.66 USD. This implies a price increase of 493.79% is expected in the next year compared to the current price of 0.28.


Analysts
Analysts52
Price Target1.66 (492.86%)
EPS Next YN/A
Revenue Next YearN/A
IOBT Forecast & Estimates

IOBT Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

IOBT Financial Highlights


Income Statements
Revenue(TTM)N/A
Net Income(TTM)N/A
Industry RankSector Rank
PM (TTM) N/A
ROA N/A
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%N/A
Sales Q2Q%N/A
EPS 1Y (TTM)N/A
Revenue 1Y (TTM)N/A
IOBT financials

IOBT Ownership

Ownership
Inst Owners46.77%
Shares71.95M
Float67.18M
Ins Owners6.63%
Short Float %6.25%
Short Ratio0.36
IOBT Ownership

IOBT Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABBV ABBVIE INC15.33406.874B
AMGN AMGEN INC16.52199.203B
GILD GILEAD SCIENCES INC16.59178.678B
VRTX VERTEX PHARMACEUTICALS INC23.77116.013B
REGN REGENERON PHARMACEUTICALS16.7280.332B
ALNY ALNYLAM PHARMACEUTICALS INC43.3742.526B
INSM INSMED INC N/A30.205B
NTRA NATERA INC N/A28.081B
BIIB BIOGEN INC11.7127.132B
UTHR UNITED THERAPEUTICS CORP17.7220.958B
MRNA MODERNA INC N/A20.742B
EXAS EXACT SCIENCES CORP341.219.757B
RVMD REVOLUTION MEDICINES INC N/A19.5B

About IOBT

Company Profile

IOBT logo image IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The firm develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The firm is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.

Company Info

IO BIOTECH INC

Ole Maaloes Veh 3

COPENHAGEN DK

Employees: 80

IOBT Company Website

IOBT Investor Relations

Phone: 4570702980

IO BIOTECH INC / IOBT FAQ

What does IO BIOTECH INC do?

IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The firm develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The firm is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.


Can you provide the latest stock price for IO BIOTECH INC?

The current stock price of IOBT is 0.28 USD. The price decreased by -6.82% in the last trading session.


Does IOBT stock pay dividends?

IOBT does not pay a dividend.


What is the ChartMill rating of IO BIOTECH INC stock?

IOBT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.


Which stock exchange lists IOBT stock?

IOBT stock is listed on the Nasdaq exchange.


When does IO BIOTECH INC (IOBT) report earnings?

IO BIOTECH INC (IOBT) will report earnings on 2026-03-16, after the market close.


Can you provide the short interest for IOBT stock?

The outstanding short interest for IO BIOTECH INC (IOBT) is 6.25% of its float.